Dual CD33/CLL1 CAR T
/ Sichuan Kelun Pharma, Beijing Boren Hospital
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
June 11, 2025
Optimized Dual CD33/CLL1 CAR T Cells in Subjects With Refractory or Relapsed Acute Myeloid Leukemia
(clinicaltrials.gov)
- P1 | N=0 | Withdrawn | Sponsor: Beijing Boren Hospital | N=20 ➔ 0 | Recruiting ➔ Withdrawn
Enrollment change • Trial withdrawal • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • CD33
1 to 1
Of
1
Go to page
1